CD24 and COVID-19: A Phase II Randomized, Single-blind Dose Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 in 10^9Dose Versus 10^10 Dose, for the Prevention of Clinical Deterioration inhalation via mouthpiece nebulization, administered in Patients With Moderate or Severe COVID-19